Pfizer’s Growing Hematology Pipeline Matures With New Hemophilia, Sickle Cell Data
Multiple Modalities Advance Across Non-Malignant Diseases
Executive Summary
The big pharma is building on its hematology legacy beyond coagulation factors with marstacimab and gene therapies for hemophilia, plus oral and injectable medicines for sickle cell disease.